Clinical Trial

PIERS and BIS, sFIT:PIGF, Adrenomedullin

Study acronym: BIS2
Recruiting
View on ClinicalTrials.gov →
Summary
Pre-eclampsia, more than being proteinuric gestational hypertension alone, is a state of exaggerated systemic inflammation and remains a leading direct cause of maternal morbidity and mortality worldwide.1 Standardization of antenatal and postnatal assessment and surveillance of pre-eclampsia with protocols that recognize the systemic inflammatory model of preeclampsia have been associated with reduced maternal morbidity.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2015-10-15; most recent amendment 2026-04-22.
Status change: Not Yet Recruiting → Recruiting 2017-08-30
Trial Details
NCT Number NCT02578810
Lead Sponsor Suez Canal University
Collaborators: University of Malaya
Conditions Eclampsia
Enrollment 48 participants
Start Date 2016-10
Primary Completion 2030-12 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-23